Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fish oil and Body's own healing molecules could lift long COVID depression

NCT ID NCT07711444

Symptom relief Sponsor: National Science and Technology Council, Taiwan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study tests whether two dietary supplements—eicosapentaenoic acid (EPA), an omega-3 fatty acid, and specialized pro-resolving lipid mediators (SPMs)—can reduce depressive symptoms in adults with long COVID. Participants take either EPA, SPMs, or a placebo daily for 12 weeks. The goal is to see if these natural compounds can improve mood and mental health after a COVID-19 infection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Eicosapentaenoic acid (omega-3 fatty acid) and Specialized Pro-Resolving Lipid Mediator (SPM)
What this could lead to
If effective, these supplements could offer a new, low-risk way to treat depression in long COVID patients.
What could go wrong
This is a small, early-stage trial, and results may not apply to everyone. Supplements can have side effects and may not outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

54 people

The number who actually took part.

Started

Jun 2024

Finished

Jun 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed SARS-CoV-2 infection by PCR, documented positive test, or clinician diagnosis * Meeting CDC criteria for Post-COVID Conditions (Long COVID) as the presence of new, returning, or ongoing symptoms ≥4 weeks after confirmed SARS-CoV-2 infection * Hamilton Depression Rating Scale (HAMD-21) score ≥18 at baseline * Stable antidepressant treatment for ≥4 weeks or no current antidepressant use; and * Ability to provide written informed consent Exclusion Criteria: * Current or past six-month diagnosis of psychotic disorder, bipolar disorder, substance use disorder, or other major psychiatric conditions based on ICD-10 or DSM-5 criteria * Significant neurological or medical comorbidities (eg, epilepsy, traumatic brain injury, autoimmune disease, cancer), acute infections, or clinically significant laboratory abnormalities * Regular use of SPM or EPA supplementation \>0·5 g/day * Known allergy or intolerance to omega-3 fatty acids or SPMs; and * Requirement for inpatient psychiatric care due to acute suicide risk

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 Depression long COVID-19 major depressive disorder post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 Depression - major depressive disorder

Contacts and locations

Locations

  • Mind-Body Interface Research Center (MBI Lab & Care)

    Taichung, Taichung, 404, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.